International Research Highlight
Genetic profiling is increasingly being used for disease classification and treatment allocation in patients with diffuse gliomas, which include glioblastoma and lower-grade gliomas. Owing to the location of these tumours, tissue sampling is challenging, particularly repeat sampling aimed at capturing disease evolution following therapy. Liquid biopsy sampling provides new opportunities in this regard, but the scope for blood-based detection of DNA derived from central nervous system (CNS) cancers might be limited by the blood–brain barrier. Now, a study reported in Nature highlights the promise of genetic profiling of gliomas via liquid biopsy of cerebrospinal fluid (CSF).
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Passend zum Thema
DKK 2020/© [M] Noppasinw / stock.adobe.com